SG165385A1 - Novel physiological substance nesfatin, substance relevant thereto, and use of the substances - Google Patents

Novel physiological substance nesfatin, substance relevant thereto, and use of the substances

Info

Publication number
SG165385A1
SG165385A1 SG201006710-6A SG2010067106A SG165385A1 SG 165385 A1 SG165385 A1 SG 165385A1 SG 2010067106 A SG2010067106 A SG 2010067106A SG 165385 A1 SG165385 A1 SG 165385A1
Authority
SG
Singapore
Prior art keywords
genes
body weight
substance
polypeptides
nesfatin
Prior art date
Application number
SG201006710-6A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Masanori Yamamoto
Masatomo Mori
Hiroyuki Shimizu
Original Assignee
Teijin Pharma Ltd
Univ Corp Gunma University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Univ Corp Gunma University filed Critical Teijin Pharma Ltd
Publication of SG165385A1 publication Critical patent/SG165385A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
SG201006710-6A 2005-06-24 2006-06-23 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances SG165385A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005184441 2005-06-24
JP2006064678 2006-03-09

Publications (1)

Publication Number Publication Date
SG165385A1 true SG165385A1 (en) 2010-10-28

Family

ID=37570595

Family Applications (2)

Application Number Title Priority Date Filing Date
SG201006710-6A SG165385A1 (en) 2005-06-24 2006-06-23 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances
SG201006711-4A SG165386A1 (en) 2005-06-24 2006-06-23 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG201006711-4A SG165386A1 (en) 2005-06-24 2006-06-23 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances

Country Status (15)

Country Link
EP (1) EP1900813A4 (fr)
JP (1) JP5640230B2 (fr)
KR (1) KR20080028888A (fr)
CN (1) CN101300346B (fr)
AU (1) AU2006260088B2 (fr)
BR (1) BRPI0612279A2 (fr)
CA (1) CA2613257A1 (fr)
IL (1) IL188288A (fr)
NO (1) NO20080412L (fr)
NZ (1) NZ565253A (fr)
RU (1) RU2418002C2 (fr)
SG (2) SG165385A1 (fr)
TW (1) TWI395948B (fr)
WO (1) WO2006137597A1 (fr)
ZA (1) ZA200711105B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155833A1 (en) 2007-04-06 2009-06-18 Teijin Pharma Limited Screening method of nesfatin-1-action regulating substance or nesfatin-1-like action substance with the use of receptor protein selected from the group consisting of gpr3, gpr6 and gpr12
WO2009025401A1 (fr) * 2007-08-23 2009-02-26 Teijin Pharma Limited Anticorps spécifique de la nesfatine-1 et son utilisation, et anticorps spécifique de la nesfatine et son utilisation
JP4691571B2 (ja) 2008-03-04 2011-06-01 株式会社マルハニチロ食品 摂食調節剤
WO2010009330A1 (fr) * 2008-07-17 2010-01-21 The Rockefeller University Compositions de protéine variante de nucléobindine i et procédés d’utilisation
WO2010028676A1 (fr) * 2008-09-09 2010-03-18 Mondobiotech Laboratories Ag Utilisation d’un peptide comme agent thérapeutique
EP2229952B1 (fr) * 2009-03-12 2014-08-13 Jian-Ning Liu Peptide plasmatique anti-diabétique NUCB2 (pladin et nesfatin-1) et ses utilisations
US9018159B2 (en) 2009-03-12 2015-04-28 Landing Biotech, Inc. Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof
AU2013336237A1 (en) 2012-10-22 2015-06-11 Sabag-Rfa Ltd A system for delivering therapeutic agents into living cells and cells nuclei
CN106589101A (zh) * 2016-11-30 2017-04-26 青岛大学 一种nesfatin多肽及其相关物质和用途
CN108949880B (zh) * 2018-08-03 2021-07-20 吉林大学 一种牛脊髓肽的制备方法及其应用
WO2021112540A1 (fr) * 2019-12-02 2021-06-10 주식회사 엘지화학 Facteur de sécrétion de protéine dérivée d'une cellule cho et vecteur d'expression comprenant celui-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
ATE78293T1 (de) 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
CA1332049C (fr) 1988-10-07 1994-09-20 Eli Lilly And Company Expression eucaryotique
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
JP2002017186A (ja) 2000-06-30 2002-01-22 Hayashibara Biochem Lab Inc トランスジェニック植物
JP2003116385A (ja) 2001-10-15 2003-04-22 Univ Of The Ryukyus 日本脳炎ワクチンをコードする遺伝子を含むトランスジェニック植物
JP2003342201A (ja) 2002-03-20 2003-12-03 Cardio Corp 遺伝子細胞治療剤
JP3887658B2 (ja) 2002-03-27 2007-02-28 新潟県 遺伝子導入用の植物細胞処理装置

Also Published As

Publication number Publication date
SG165386A1 (en) 2010-10-28
NO20080412L (no) 2008-03-18
EP1900813A4 (fr) 2009-08-05
TW200741205A (en) 2007-11-01
IL188288A0 (en) 2008-04-13
EP1900813A1 (fr) 2008-03-19
RU2008102731A (ru) 2009-07-27
IL188288A (en) 2013-08-29
CN101300346B (zh) 2013-04-24
CA2613257A1 (fr) 2006-12-28
CN101300346A (zh) 2008-11-05
KR20080028888A (ko) 2008-04-02
NZ565253A (en) 2011-06-30
JP5640230B2 (ja) 2014-12-17
BRPI0612279A2 (pt) 2009-01-27
JPWO2006137597A1 (ja) 2009-01-22
TWI395948B (zh) 2013-05-11
WO2006137597A9 (fr) 2008-05-29
ZA200711105B (en) 2009-08-26
RU2418002C2 (ru) 2011-05-10
AU2006260088A1 (en) 2006-12-28
WO2006137597A1 (fr) 2006-12-28
AU2006260088B2 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
SG165386A1 (en) Novel physiological substance nesfatin, substance relevant thereto, and use of the substances
MY176679A (en) Use of nutritional compositions for preventing disorders
IL225203A (en) An isolated complementary factor polypeptide, methods for its preparation, its uses and a factor that lowers its expression or activity
WO2008054200A3 (fr) Utilisation de compositions nutritives pour empêcher des troubles
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143098A8 (fr) Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
TW200630360A (en) Polymorphs of {5-[3-(4,6-difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
AP2006003778A0 (en) 5,6-Dialkyl-7-amino-triazolopyrimidines, method for their production, their use for controlling pat hogenic fungi and agents containing said compounds
WO2008036678A3 (fr) Modulation induite par ppar de la neurogenèse
WO2006015060A3 (fr) Composes isoindoline et methodes d'utilisation de ces derniers
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2010029089A3 (fr) Polythérapie pour le traitement du diabète et des états pathologiques apparentés
DE602006016760D1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
GB2478065A (en) Method and systems for personalized action plans
WO2008039566A3 (fr) Médicaments et utilisations
ZA200606834B (en) 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer's disease
EP2674165A3 (fr) Agonistes de recepteur du facteur de croissance des hepatocytes pour l'augementation de lymphangiogenèse
WO2005115446A3 (fr) Detection et utilisation de prolylcarboxypeptidase
DE602006006068D1 (de) Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd
WO2005115548A3 (fr) Traitement de troubles depressifs
WO2006034296A3 (fr) Composes amino inhibant l'activite de la beta-secretase et methodes d'utilisation
WO2006048877A3 (fr) Traitement des pathologies malignes du lymphocyte b
EP1734056A4 (fr) Procede de modification de gomme arabique; gomme arabique modifiée obtenue par le procede et utilisation de cette derniere